Spyre Therapeutics (SYRE) Competitors $16.60 +0.25 (+1.55%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYRE vs. ADMA, ZLAB, AKRO, TLX, PTCT, LNTH, APLS, MLTX, PTGX, and MIRMShould you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include ADMA Biologics (ADMA), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Telix Pharmaceuticals (TLX), PTC Therapeutics (PTCT), Lantheus (LNTH), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Spyre Therapeutics vs. Its Competitors ADMA Biologics Zai Lab Akero Therapeutics Telix Pharmaceuticals PTC Therapeutics Lantheus Apellis Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Mirum Pharmaceuticals Spyre Therapeutics (NASDAQ:SYRE) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Does the media favor SYRE or ADMA? In the previous week, ADMA Biologics had 12 more articles in the media than Spyre Therapeutics. MarketBeat recorded 13 mentions for ADMA Biologics and 1 mentions for Spyre Therapeutics. ADMA Biologics' average media sentiment score of 1.59 beat Spyre Therapeutics' score of 0.59 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is SYRE or ADMA more profitable? ADMA Biologics has a net margin of 44.06% compared to Spyre Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 41.01% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -71.30% -38.69% ADMA Biologics 44.06%41.01%28.47% Which has more volatility and risk, SYRE or ADMA? Spyre Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Do analysts recommend SYRE or ADMA? Spyre Therapeutics currently has a consensus target price of $53.40, suggesting a potential upside of 221.61%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 60.90%. Given Spyre Therapeutics' higher possible upside, analysts clearly believe Spyre Therapeutics is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do insiders and institutionals hold more shares of SYRE or ADMA? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 15.4% of Spyre Therapeutics shares are held by insiders. Comparatively, 3.5% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, SYRE or ADMA? ADMA Biologics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,126.83-$208.02M-$3.40-4.88ADMA Biologics$426.45M9.62$197.67M$0.8619.99 SummaryADMA Biologics beats Spyre Therapeutics on 10 of the 17 factors compared between the two stocks. Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRE vs. The Competition Export to ExcelMetricSpyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$996.60M$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-4.8520.4630.4325.11Price / Sales1,126.83237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book3.347.959.016.20Net Income-$208.02M-$54.72M$3.26B$265.38M7 Day Performance-1.52%1.56%1.00%-1.25%1 Month Performance1.55%5.71%4.19%-0.81%1 Year Performance-37.51%9.01%28.39%18.83% Spyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRESpyre Therapeutics2.8636 of 5 stars$16.60+1.6%$53.40+221.6%-38.7%$996.60M$890K-4.8573ADMAADMA Biologics4.353 of 5 stars$17.63+3.8%$27.67+56.9%-3.5%$4.05B$474.17M20.50530Positive NewsZLABZai Lab2.8001 of 5 stars$35.69-0.1%$57.22+60.3%+96.0%$3.97B$398.99M-17.501,869Insider TradeAKROAkero Therapeutics3.9484 of 5 stars$48.59-1.6%$81.57+67.9%+79.3%$3.95BN/A-24.3030News CoverageTLXTelix PharmaceuticalsN/A$11.90+3.1%$22.33+87.7%N/A$3.91B$516.72M0.00N/ANews CoverageGap UpHigh Trading VolumePTCTPTC Therapeutics4.4312 of 5 stars$49.80+2.0%$70.15+40.9%+42.0%$3.88B$1.76B7.141,410Trending NewsAnalyst ForecastAnalyst RevisionLNTHLantheus4.7548 of 5 stars$55.97+3.3%$105.50+88.5%-43.0%$3.68B$1.52B14.89700APLSApellis Pharmaceuticals4.513 of 5 stars$27.35-1.4%$34.12+24.7%-31.8%$3.50B$781.37M-15.03770Insider TradeShort Interest ↑MLTXMoonLake Immunotherapeutics1.5991 of 5 stars$53.73-1.2%$74.43+38.5%+9.4%$3.49BN/A-19.332PTGXProtagonist Therapeutics1.9812 of 5 stars$56.21+0.2%$67.20+19.6%+35.5%$3.49B$434.43M80.30120Positive NewsMIRMMirum Pharmaceuticals3.4575 of 5 stars$66.68-1.8%$74.13+11.2%+62.7%$3.41B$336.89M-55.11140 Related Companies and Tools Related Companies ADMA Competitors ZLAB Competitors AKRO Competitors TLX Competitors PTCT Competitors LNTH Competitors APLS Competitors MLTX Competitors PTGX Competitors MIRM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRE) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access